DE69907152D1 - Krebsbehandlung - Google Patents

Krebsbehandlung

Info

Publication number
DE69907152D1
DE69907152D1 DE69907152T DE69907152T DE69907152D1 DE 69907152 D1 DE69907152 D1 DE 69907152D1 DE 69907152 T DE69907152 T DE 69907152T DE 69907152 T DE69907152 T DE 69907152T DE 69907152 D1 DE69907152 D1 DE 69907152D1
Authority
DE
Germany
Prior art keywords
cancer treatment
cancerous
elevation
testing
cdk1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69907152T
Other languages
English (en)
Inventor
Meek Warenius
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theryte Ltd
Original Assignee
Theryte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9803446A external-priority patent/GB2334577A/en
Priority claimed from GB9803447A external-priority patent/GB2334578A/en
Priority claimed from GBGB9812151.0A external-priority patent/GB9812151D0/en
Priority claimed from GB9814545A external-priority patent/GB2334579B/en
Priority claimed from GB9903035A external-priority patent/GB2335739A/en
Application filed by Theryte Ltd filed Critical Theryte Ltd
Application granted granted Critical
Publication of DE69907152D1 publication Critical patent/DE69907152D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4748—Details p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69907152T 1998-02-18 1999-02-18 Krebsbehandlung Expired - Lifetime DE69907152D1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9803446A GB2334577A (en) 1998-02-18 1998-02-18 Resistance of p53 mutant cancer cells to cytoxic effects of (chemo)therapeutic agents involving assay of cyclin D1 protein
GB9803447A GB2334578A (en) 1998-02-18 1998-02-18 Diagnosis of cancer involving assay of levels of cyclin-dependent kinase (CDK) isoenzymes
GBGB9812151.0A GB9812151D0 (en) 1998-06-05 1998-06-05 Treating cancer
GB9814545A GB2334579B (en) 1998-02-18 1998-07-03 Treating cancer
GB9903035A GB2335739A (en) 1998-02-18 1999-02-10 Screening anti-cancer agents
PCT/GB1999/000502 WO1999042090A2 (en) 1998-02-18 1999-02-18 Treating cancer

Publications (1)

Publication Number Publication Date
DE69907152D1 true DE69907152D1 (de) 2003-05-28

Family

ID=27517448

Family Applications (6)

Application Number Title Priority Date Filing Date
DE69907151T Expired - Lifetime DE69907151D1 (de) 1998-02-18 1999-02-18 Krebsbehandlung
DE69907155T Expired - Fee Related DE69907155T2 (de) 1998-02-18 1999-02-18 Krebsbehandlung
DE69907153T Expired - Fee Related DE69907153T2 (de) 1998-02-18 1999-02-18 Krebsbehandlung
DE69907156T Expired - Fee Related DE69907156T2 (de) 1998-02-18 1999-02-18 Krebsbehandlung
DE69907154T Expired - Fee Related DE69907154T2 (de) 1998-02-18 1999-02-18 Krebsbehandlung
DE69907152T Expired - Lifetime DE69907152D1 (de) 1998-02-18 1999-02-18 Krebsbehandlung

Family Applications Before (5)

Application Number Title Priority Date Filing Date
DE69907151T Expired - Lifetime DE69907151D1 (de) 1998-02-18 1999-02-18 Krebsbehandlung
DE69907155T Expired - Fee Related DE69907155T2 (de) 1998-02-18 1999-02-18 Krebsbehandlung
DE69907153T Expired - Fee Related DE69907153T2 (de) 1998-02-18 1999-02-18 Krebsbehandlung
DE69907156T Expired - Fee Related DE69907156T2 (de) 1998-02-18 1999-02-18 Krebsbehandlung
DE69907154T Expired - Fee Related DE69907154T2 (de) 1998-02-18 1999-02-18 Krebsbehandlung

Country Status (8)

Country Link
US (3) US6521407B1 (de)
EP (7) EP1057032B1 (de)
JP (7) JP2002504353A (de)
AT (6) ATE238555T1 (de)
AU (8) AU749180B2 (de)
CA (7) CA2321481A1 (de)
DE (6) DE69907151D1 (de)
WO (8) WO1999042835A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6995249B1 (en) * 1998-08-14 2006-02-07 Japan Science And Technology Corporation Nucleic acid capable of binding specifically to Ras target protein
ATE556713T1 (de) * 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
US8124630B2 (en) * 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
AU2001245939A1 (en) * 2000-03-24 2001-10-08 Millennum Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention, and therapy of human cancers
AU2001259160A1 (en) * 2000-04-28 2001-11-12 Millennium Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention, and therapy of human cancers
US6905816B2 (en) 2000-11-27 2005-06-14 Intelligent Medical Devices, Inc. Clinically intelligent diagnostic devices and methods
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
US7838541B2 (en) 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
JP2003304884A (ja) * 2002-02-13 2003-10-28 Japan Found Cancer Res 抗がん剤の適合性予測方法
GB2387385A (en) * 2002-03-25 2003-10-15 Theryte Ltd Chemotherapeutic agents for treating cancer
US7989176B2 (en) * 2002-03-25 2011-08-02 Theryte Ltd. Treating cancer
AU2003249340A1 (en) * 2002-06-18 2003-12-31 Irm Llc Diagnosis and treatment of chemoresistant tumors
EP1600513B1 (de) * 2003-02-26 2010-02-24 Sysmex Corporation Verfahren zur untersuchung einer zelle
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
PT1626714E (pt) * 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diarilureias para doenças mediadas por pdgfr
BR122016015715B8 (pt) 2003-07-23 2021-05-25 Bayer Healthcare Llc composições farmacêuticas de metilamida de ácido 4[4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenóxi)-piridina-2-carboxílico
US20050136177A1 (en) * 2003-08-25 2005-06-23 Anthony Hesse Method for coloring landscaping materials using foamable dry colorant
US8021831B2 (en) 2003-08-25 2011-09-20 Board Of Regents, The University Of Texas System Taxane chemosensitivity prediction test
AU2005215910B2 (en) * 2004-02-23 2008-05-01 Novartis Ag P53 wild-type as biomarker for the treatment with mTOR inhibitors in combination with a cytotoxic agent
US20060019268A1 (en) * 2004-03-26 2006-01-26 Research Development Foundation Molecular markers of cisplatin resistance in cancer and uses thereof
EP1767647B1 (de) 2004-05-31 2010-11-24 Sysmex Corporation Verfahren zur beurteilung der malignität einer säuger-krebszelle
CN102634574B (zh) * 2004-12-08 2014-11-12 安万特药物公司 测量对多西他赛抗药性或敏感性的方法
JP4944446B2 (ja) * 2005-01-31 2012-05-30 シスメックス株式会社 抗がん剤治療の有効性予測方法
US7957910B2 (en) * 2005-01-31 2011-06-07 Sysmex Corporation Method for predicting effectiveness of chemotherapy
JP5190654B2 (ja) * 2005-03-31 2013-04-24 国立大学法人広島大学 分子マーカーを用いた間葉系幹細胞の識別方法及びその利用
US20100279994A1 (en) * 2005-06-21 2010-11-04 Inifinity Discovery, Inc. Ansamycin Formulations and Methods of Use Thereof
JP5046574B2 (ja) * 2005-06-30 2012-10-10 シスメックス株式会社 抗がん剤治療の有効性予測方法
US7682785B2 (en) 2005-06-30 2010-03-23 Sysmex Corporation Method for predicting effectiveness of chemotherapy using anticancer agent
JP4766969B2 (ja) 2005-09-14 2011-09-07 シスメックス株式会社 組織性質判定装置
WO2007062222A2 (en) * 2005-11-22 2007-05-31 University Of South Florida Inhibition of cell proliferation
JP5111902B2 (ja) * 2007-03-14 2013-01-09 シスメックス株式会社 癌の診断支援装置
WO2008115561A2 (en) * 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
MX2009010808A (es) * 2007-04-12 2009-10-29 Infinity Discovery Inc Formulaciones de ansamicina de hidroquinona.
EP2028600B1 (de) 2007-08-24 2016-10-26 Sysmex Corporation Diagnose-Hilfssystem für Krebs, Diagnosehilfe für Informationen über das Krebsverfahren und Computerprogrammprodukt
GB0804496D0 (en) 2008-03-11 2008-04-16 Theryte Ltd Treating cancer
US20100184851A1 (en) * 2008-08-29 2010-07-22 University Of South Florida Inhibition of cell proliferation
KR20110090925A (ko) 2008-10-15 2011-08-10 인피니티 파마슈티컬스, 인코포레이티드 안사마이신 하이드로퀴논 조성물
WO2010135426A1 (en) * 2009-05-19 2010-11-25 Infinity Pharmaceuticals, Inc. Methods of treating liposarcoma

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK354487A (da) * 1986-07-11 1988-01-12 Noboru Yanaihara Oncogen-relaterede peptider
CA1339069C (en) * 1987-11-09 1997-07-29 Henry Lee Niman Polypeptide-induced monoclonal receptors to protein ligand
WO1991019006A1 (en) * 1990-06-01 1991-12-12 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce MONOCLONAL ANTIBODIES FOR IDENTIFICATION AND PREPARATION OF raf-1 ONCOPROTEIN
DE69333043T2 (de) * 1992-10-16 2004-05-06 Cold Spring Harbor Laboratory Umlagerung des cyclin komlexes und seine darauf bezogenen anwendungen
US5381224A (en) * 1993-08-30 1995-01-10 A. E. Dixon Scanning laser imaging system
DE4444969C1 (de) * 1994-12-16 1996-10-24 Orga Med Dr Med Erwin Klopfer Nachweis von Antikörpern gegen p53 in Körperflüssigkeiten
AU6593196A (en) * 1995-07-20 1997-02-18 Paracelsian, Inc. Determination of the presence of abnormal cellular proliferation through the detection of one or more cyclin dependent kinases
US5714329A (en) * 1995-11-29 1998-02-03 Sequana Theraputics, Inc. Methods for the diagnosis of a genetic predisposition to cancer associated with variant CDK4 allele
AU714560B2 (en) * 1996-04-15 2000-01-06 Trustees Of The University Of Pennsylvania, The Sensitization of cells to radiation and chemotherapy
JP4205165B2 (ja) * 1996-05-08 2009-01-07 サイクラセル リミテッド Ｃｄｋ４活性の阻害のための方法と手段
WO1998034118A1 (en) * 1997-01-30 1998-08-06 Yale University Diagnostic methods and compositions based on the distribution of rad51

Also Published As

Publication number Publication date
DE69907156T2 (de) 2004-02-12
JP2002504687A (ja) 2002-02-12
EP1057031A1 (de) 2000-12-06
CA2321458A1 (en) 1999-08-26
JP2002504688A (ja) 2002-02-12
DE69907156D1 (de) 2003-05-28
WO1999042828A2 (en) 1999-08-26
JP2002503822A (ja) 2002-02-05
WO1999042821A2 (en) 1999-08-26
AU749180B2 (en) 2002-06-20
CA2321438A1 (en) 1999-08-26
EP1057030B1 (de) 2003-04-23
US6878526B1 (en) 2005-04-12
US6521407B1 (en) 2003-02-18
JP2002504496A (ja) 2002-02-12
WO1999042090A2 (en) 1999-08-26
ATE238554T1 (de) 2003-05-15
DE69907153D1 (de) 2003-05-28
AU2538099A (en) 1999-09-06
CA2321482A1 (en) 1999-08-26
AU2630199A (en) 1999-09-06
WO1999042834A3 (en) 1999-11-25
DE69907155D1 (de) 2003-05-28
WO1999042835A1 (en) 1999-08-26
EP1057031B1 (de) 2003-04-23
WO1999042836A1 (en) 1999-08-26
AU2538199A (en) 1999-09-06
AU741632B2 (en) 2001-12-06
AU2630099A (en) 1999-09-06
WO1999042834A2 (en) 1999-08-26
EP1057027A2 (de) 2000-12-06
WO1999042839A2 (en) 1999-08-26
JP2002504683A (ja) 2002-02-12
JP2002504354A (ja) 2002-02-12
AU2538299A (en) 1999-09-06
EP1057028A1 (de) 2000-12-06
AU743454B2 (en) 2002-01-24
DE69907154T2 (de) 2004-02-19
AU2538499A (en) 1999-09-06
AU739001B2 (en) 2001-10-04
EP1057032A2 (de) 2000-12-06
US20030134315A1 (en) 2003-07-17
ATE238558T1 (de) 2003-05-15
CA2321479A1 (en) 1999-08-26
EP1057032B1 (de) 2003-04-23
ATE238556T1 (de) 2003-05-15
EP1057029B1 (de) 2003-04-23
WO1999042090A3 (en) 1999-11-04
ATE238555T1 (de) 2003-05-15
EP1057033A1 (de) 2000-12-06
EP1057030A2 (de) 2000-12-06
EP1057028B1 (de) 2003-04-23
AU741712B2 (en) 2001-12-06
WO1999042821A3 (en) 1999-11-11
WO1999042837A1 (en) 1999-08-26
JP2002504353A (ja) 2002-02-12
AU753588B2 (en) 2002-10-24
AU2537999A (en) 1999-09-06
WO1999042828A3 (en) 2000-08-24
CA2321467A1 (en) 1999-08-26
ATE238553T1 (de) 2003-05-15
DE69907154D1 (de) 2003-05-28
AU735896B2 (en) 2001-07-19
DE69907155T2 (de) 2004-02-05
EP1057029A2 (de) 2000-12-06
CA2321481A1 (en) 1999-08-26
ATE238557T1 (de) 2003-05-15
DE69907153T2 (de) 2004-01-29
DE69907151D1 (de) 2003-05-28
EP1057033B1 (de) 2003-04-23
WO1999042839A3 (en) 1999-10-28
CA2321480A1 (en) 1999-08-26
AU2538599A (en) 1999-09-06

Similar Documents

Publication Publication Date Title
ATE238555T1 (de) Krebsbehandlung
ES2148171T3 (es) Gen mutado en cancer colorrectal de humanos.
BRPI9912227B8 (pt) método para diagnóstico precoce in vitro de carcinomas e de seus estágios iniciais e kit para realização do método.
AU4085097A (en) Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer
EP1035215A3 (de) Verfahren und Sondenset zur Erkennung von Krebs
AU2001253079A1 (en) Methods, compositions and kits for the detection and monitoring of breast cancer
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
EP1092772A4 (de) Antikörper gegen eine lar-phosphatase untereinheit
AU9779498A (en) Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
AU7868300A (en) Prostate cancer marker proteins
AU2002315411A1 (en) Detection and treatment of prostate cancer
WO2002023200A3 (en) Human breast cancer biomarkers
AU2001267630A1 (en) Immunological test and diagnostic kit for prostate adenocarcinoma
AU2001294165A1 (en) Apparatus for prostate cancer diagnose
AU2002306568A1 (en) Forms of prostate specific antigens and methods for their detection
WO2004093662A3 (en) Method for detecting prognosis of cancer
WO2003058198A3 (en) Human breast cancer biomarkers
UA42589A (uk) Спосіб діагностики гомеостазу
UA70269A (en) Method of the preoperational differential diagnosis of the benign and malignant tumors of the thyroid gland

Legal Events

Date Code Title Description
8332 No legal effect for de